Welcome to our dedicated page for Vertex Pharmaceuticals news (Ticker: VRTX), a resource for investors and traders seeking the latest updates and insights on Vertex Pharmaceuticals stock.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) is a global biotechnology company with approved medicines in cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and a broad pipeline across kidney disease, neuropathic pain, type 1 diabetes and other serious conditions. The VRTX news feed on Stock Titan brings together company press releases and other coverage that highlight how its commercial portfolio and research programs are evolving over time.
News about Vertex often focuses on clinical data readouts, regulatory milestones and commercial updates. Recent announcements have covered progress in cystic fibrosis, including data on ALYFTREK and other CFTR modulators presented at scientific conferences, and updates on next-generation CFTR correctors and CFTR mRNA therapies. Vertex also regularly reports on CASGEVY, its CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, including longer-term outcomes data and plans for regulatory submissions in additional age groups.
Investors and followers of VRTX news can also expect updates on JOURNAVX, the company’s oral non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in adults, including information on prescription trends, payer coverage and hospital formulary adoption. In kidney diseases, Vertex issues news on povetacicept and inaxaplin, including Phase 1/2 and Phase 3 trial data in IgA nephropathy, primary membranous nephropathy and APOL1-mediated kidney disease, as well as regulatory designations such as Breakthrough Therapy and Fast Track.
Additional news items may include financial results, participation in major healthcare investor conferences, and updates on programs in type 1 diabetes, autosomal dominant polycystic kidney disease and myotonic dystrophy type 1. For anyone tracking VRTX stock, this news page offers a centralized view of how Vertex’s marketed products and pipeline advance through clinical development, regulatory review and commercialization.
Vertex Pharmaceuticals (NASDAQ: VRTX) has announced its management team's participation in three upcoming investor conferences in May and June 2025:
1. Evercore Biotechnology Summit (May 21) - Featuring Susie Lisa, SVP of Investor Relations, and Manisha Pai, Executive Director of IR
2. Bernstein 41st Annual Strategic Decisions Conference (May 30) - CEO Dr. Reshma Kewalramani will participate in a fireside chat at 8:00 a.m. ET
3. Goldman Sachs 46th Annual Global Healthcare Conference (June 10) - Dr. Kewalramani and Dr. David Altshuler, EVP of Global Research and CSO, will join a fireside chat at 2:40 p.m. ET
Live webcasts will be available on Vertex's website with replays archived in the Investors section.
Vertex Pharmaceuticals (Nasdaq: VRTX) announced that Paul Negulescu, Ph.D., Senior Vice President, has been awarded the prestigious 2025 Canada Gairdner International Award for his groundbreaking research in cystic fibrosis (CF). The award recognizes his pioneering work in understanding CF's cellular and molecular mechanisms, leading to transformative drug therapies.
Under Negulescu's leadership, Vertex developed the first-ever protein folding corrector medicines that treat CF's underlying cause. The company's most recent achievement is a triple combination therapy that can treat over 90% of CF patients with more than 300 different mutations through once-daily dosing.
Vertex currently has five approved CF medicines that restore function of the defective CFTR protein. The research team continues to develop new therapies, including an mRNA approach in clinical development, targeting the remaining 10% of patients who don't respond to existing treatments.
Vertex Pharmaceuticals (Nasdaq: VRTX) has scheduled its first quarter 2025 financial results announcement for Monday, May 5, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss the results.
Investors can access the call by dialing (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and referencing the 'Vertex Pharmaceuticals First Quarter 2025 Earnings Call.' A live webcast will be available through the Investors section of Vertex's website at www.vrtx.com. Participants are advised to register 15 minutes before the scheduled webcast to ensure timely connection. An archived version of the webcast will be available on the company's website.
Vertex Pharmaceuticals (VRTX) has received European Commission approval for an expanded label of KAFTRIO® in combination with ivacaftor for treating cystic fibrosis (CF). The expansion covers patients aged 2 years and older with at least one non-class I mutation in the CFTR gene.
This regulatory approval makes approximately 4,000 additional people in the European Union eligible for this treatment that addresses the underlying cause of their disease. Several countries including Austria, Denmark, Ireland, Norway, Sweden, and Germany will provide immediate access to eligible patients through existing reimbursement agreements.
Vertex Pharmaceuticals (VRTX) has announced significant updates to its Type 1 diabetes (T1D) portfolio. The company reported that while VX-264, their encapsulated pancreatic islet cell therapy, was safe and well-tolerated, it failed to meet efficacy endpoints and will not advance further in clinical trials.
On a positive note, zimislecel (formerly VX-880), their fully differentiated islet cell therapy, is progressing well in Phase 3 trials. The pivotal trial is expected to complete enrollment and dosing in H1 2025, with global regulatory submissions planned for 2026. If approved, zimislecel could benefit approximately 60,000 people with severe T1D across the U.S. and Europe.
The company continues to pursue research-stage T1D programs, including alternative immunosuppressive regimens, gene-edited hypoimmune stem-cell derived islet cell therapies, and novel encapsulation devices.
Vertex Pharmaceuticals (VRTX) has received UK MHRA approval for ALYFTREK®, a once-daily triple combination CFTR modulator therapy for cystic fibrosis treatment. The medication is approved for patients 6 years and older with at least one F508del mutation or another responsive mutation in the CFTR gene.
In head-to-head clinical trials, ALYFTREK demonstrated non-inferior ppFEV1 results and improved sweat chloride levels compared to existing treatments. This marks Vertex's fifth CFTR modulator regimen, offering a more flexible and less burdensome treatment option.
The company is currently working with NICE and NHS to ensure patient access in the UK. ALYFTREK received FDA approval in December 2024, with additional regulatory applications pending in Europe, Canada, Switzerland, Australia, and New Zealand.
Vertex Pharmaceuticals (VRTX) received a positive opinion from the European Medicines Agency's CHMP for expanding the label of KAFTRIO® in combination with ivacaftor. The expansion would cover the treatment of cystic fibrosis (CF) patients aged 2 years and older who have at least one non-class I mutation in the CFTR gene.
If approved, this expansion would make approximately 4,000 additional patients in the European Union eligible for CFTR modulator treatment that addresses the underlying cause of their disease. Currently, KAFTRIO is approved in the EU for CF patients aged 2 years and older with at least one copy of the F508del mutation in the CFTR gene.
Vertex Pharmaceuticals (VRTX) has announced its participation in three major investor conferences in March 2025. Stuart Arbuckle, EVP and COO, and David Altshuler, EVP of Global Research and CSO, will join a fireside chat at the TD Cowen 45th Annual Health Care Conference on March 3 at 3:10 p.m. ET.
Charles Wagner, EVP and CFO, along with Dr. Altshuler, will participate in the 2025 Leerink Partners Global Healthcare Conference on March 10 at 10:00 a.m. ET. Additionally, Susie Lisa, SVP of Investor Relations, and Miroslava Minkova, Executive Director of IR, will attend the Jefferies Biotech on the Beach Summit on March 11.
Live webcasts of management presentations will be accessible through the company's website at www.vrtx.com under the Investors section, with replays available afterward.